The study followed 38 immunocompromised adults, aged 64 to 72, who received either the Arexvy or Abrysvo RSV vaccine. Researchers found that people aged 60 and older who are immunocompromised ...

Researchers have shown that people 60 years or older with weakened immunity do not respond as strongly to vaccines against the respiratory syncytial virus (RSV) as people in the same age group with ...

Respiratory illness activity is currently considered "high" in the United States, according to the CDC. In one state, it is ...

A review and meta-analysis of data from 28 countries found significant increases in resistance to clarithromycin, ...

Approximately 40% of participants did not seroconvert or achieve a conservative neutralization threshold post-vaccination.

BARS-13 is under clinical development by Beijing Advaccine Biotechnology and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections.

Opaganib is under clinical development by RedHill Biopharma and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity—primarily organ transplant ...

Feeling ill after that Christmas or New Year's Eve party? If could be RSV. But how can you know for sure? Here are the ...

New Hampshire was the state with the highest level of respiratory illness activity, according to the CDC. Americans can prevent the spread of viruses in several ways, such as staying home when they ...

“Dr. Chen Chih-jung of Linkou Chang Gung Memorial Hospital stated in an interview on Thursday that hMPV is similar to ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...